Zymeworks Inc

Zymeworks Inc. is a biopharmaceutical company. It engages in the discovery, development, and commercialization of multifunctional biotherapeutics, initially focused on the treatment of cancer. The company is headquartered in Middletown, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zymeworks reports turnaround year with strong financials and R&D progress

Zymeworks delivered a strong financial performance in 2022, driven by revenue growth and cost management efforts.
The company faces challenges in managing increased expenses and addressing analyst inquiries on data disclosure and product development.
Despite challenges, Zymeworks remains well-positioned with ample cash resources and a robust R&D pipeline for future growth.
Opportunities lie in expanding partnerships, leveraging positive trial data, and showcasing innovation at upcoming industry events.

Zymeworks Inc reports revenue growth and strategic R&D advancements

Zymeworks Inc's Q1 2023 performance reflects positive financial trends and advancements in their R&D programs and partnerships.
While challenges exist with the Jazz agreement and future clinical trials, the company is strategically positioned for growth.
Opportunities in global collaborations, capital allocation, and innovative therapies position Zymeworks for future success and market expansion.

Zymeworks reports improved financials, advances global clinical expertise

Zymeworks Inc's Q2 2023 performance reflects a mixed financial picture with revenue growth but increased expenses, while maintaining a healthy cash position.
The company's strengths lie in advancing its product pipeline, leveraging partnerships for efficient development, and establishing global clinical expertise.
Challenges include timeline uncertainties, competitive landscape considerations, and operational complexities in clinical trial development.
Opportunities abound in therapeutic advancements, strategic partnerships, and long-term financial sustainability through disciplined management.

Zymeworks Inc reports improved financials and optimistic drug outlook

Zymeworks Inc's Q3 2023 performance reflects improved financials driven by revenue growth from collaborations, cost management strategies, and operational streamlining.
The company's strengths lie in new IND candidates, positive outlook on key drug opportunities, and confidence in study designs and treatment efficacy.
Challenges include managing expense trajectories, balancing cost structures, and optimizing cash resources for sustained operations and growth.
Opportunities abound in continued collaboration benefits, pipeline expansion in targeted cancer therapies, and advancements in preclinical assets for future clinical studies.

Zymeworks accelerates pipeline development with positive clinical results and partnerships

Zymeworks demonstrated positive performance in clinical trials and financial management in Q4 2023.
Strengths lie in pipeline progress, resource independence, and potential milestone payments.
Challenges include financial losses, competition, and the need for strategic partnerships.
Opportunities exist in partnerships, milestone payments, and upcoming data readouts for market impact.

Zymeworks Inc reports Q1 loss, focuses on T cell enhancement

Zymeworks Inc is strategically positioned to advance its clinical development programs and strengthen its presence in key locations for upcoming trials. The company is committed to executing its plan efficiently, focusing on enhancing T cell responses and exploring opportunities for sustainable growth.

Zymeworks reports Q2 losses, advances oncology pipeline with FDA clearances

Zymeworks' Q2 2024 performance reflects a mix of financial challenges and strategic advancements in drug development and regulatory milestones.
The company's strengths lie in its pipeline progress, strategic decision-making, and focus on growth through key appointments and partnerships.
While facing challenges in financial metrics and product timelines, Zymeworks has opportunities to leverage its resources for future growth and innovation.

Zymeworks reports revenue decline but showcases strength in innovation and financial strategy

Zymeworks reported a decline in revenue and a net loss for Q3 2024, reflecting ongoing financial challenges.
Despite this, the company showcased strengths in preclinical data, share repurchase program, and commitment to innovation.
Navigating market conditions and managing expenses will be crucial, but Zymeworks has opportunities in new therapeutic areas and strategic initiatives.
Investors should monitor the company's progress, especially with the upcoming R&D Day and potential advancements in its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Medpace Holdings

Vertex Pharmaceuticals

The pandemic pushed major biotech stocks into the spotlight as vaccine demands rose to unprecedented highs. Investors flocked to the industry in the next few years after the COVID-19 breakout.

Next Wave Biotech: 3 Stocks Poised for Breakthrough Success

Bancolombia

Comtech Telecommunications

Cinemark Holdings

Mr. Cooper Group Inc

Shift4 Payments

Innovative Industrial Properties

When you hear the term “growth stocks,” you probably think of high-growth yet unprofitable companies diluting shareholders through secondary offerings just to fund more losses. But that doesn't always have to be the case.

The 7 Best Bargain Growth Stocks to Buy Before 2024

Zymeworks showed positive results from the phase 1b/2 study using zanidatamab + chemotherapy + tislelizumab for the treatment of 1st-line HER2-positive G/GEJC. Results from the phase 3 HERIZON-GEA-01 study, using zanidatamab + chemotherapy + tislelizumab for treatment of 1st-line HER2-positive G/GEJC, are expected in 2024. Multiple IND filings are expected in 2024 and 2025 because of the "5 by 5" strategy that it has incorporated for its pipeline.

Zymeworks: Late-Stage Study Data In 2024 Makes This A Must-Watch

The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Zymeworks Inc. (ZYME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Zymeworks Inc. (ZYME) Have the Potential to Rally 42.84% as Wall Street Analysts Expect?

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:

Zymeworks Announces Participation in Upcoming Investor Conference

Azul

JAKKS Pacific

After over a decade of smooth sailing, stocks have been exceptionally turbulent for the past three years. Rising rates, high inflation, recession fears – you name it, and the bears have used it to maul share prices across the board.

3 Beaten-Down Stocks to Buy for 1,000% Upside in Five Years

The consensus price target hints at a 64.6% upside potential for Zymeworks Inc. (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 64.61% Upside in Zymeworks Inc. (ZYME): Here's What You Should Know

Zymeworks Inc. (NASDAQ:ZYME ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Shrinal Inamdar – Director-Investor Relations Chris Astle – Senior Vice President and Chief Financial Officer Paul Moore – Chief Scientific Officer Ken Galbraith – Chair and Chief Executive Officer Conference Call Participants Jonathan Miller – Evercore Ashiq Mubarack – Citi Charles Zhu – Guggenheim Securities Ivy Wang – Jefferies Stephen Willey – Stifel Brian Cheng – JPMorgan Operator Good day, and thank you for standing by. Welcome to the Zymeworks Third Quarter 2023 Results Conference Call.

Zymeworks Inc. (ZYME) Q3 2023 Earnings Call Transcript

VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the three and nine months ended September 30, 2023 and provided a summary of recent business highlights.

Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results

VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2023 financial results after market close on November 7, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. Eastern Time (ET).

Zymeworks To Host Third Quarter 2023 Results Conference Call

VANCOUVER, British Columbia, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced that its board of directors will nominate Dr. Nancy Davidson for election to its board of directors at the Company's upcoming annual general meeting of stockholders to be held on December 7, 2023.

Zymeworks Announces New Director Nominee

Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results in clinical trials and has been partnered with larger pharmaceutical companies. The company also has a pipeline of early-stage candidates and a potential for substantial upside through its partnerships and commercialization of zanidatamab.

Adding Zymeworks To My Value Watchlist (Initial Buy Rating)

Zymeworks, a biotech firm, specializes in biotherapeutics for cancers, with primary product zanidatamab targeting HER2 and collaborations with BeiGene and Jazz Pharmaceuticals. Financially robust with $431.4M cash, revenue surged due to a Jazz deal, has substantial growth, and promising clinical data for zanidatamab, especially for HER2-positive biliary tract cancer. Recommendation: Zymeworks is a "Strong Buy" for risk-tolerant investors due to undervaluation, product potential, and strategic partnerships.

Zymeworks' Robust Financials And The Potential Biotech Resurgence

Intuitive Surgical

Livanova

Pfizer

UnitedHealth Group

Viking Therapeutics

Zimmer Biomet Hlds

Investors always hope to buy low and sell high. In order to do so, it's necessary to identify stocks that are undervalued.

The 7 Most Undervalued Healthcare Stocks to Buy Now: August 2023

Zymeworks Inc. (NASDAQ:ZYME ) Q2 2023 Earnings Call August 10, 2023 4:30 PM ET Company Participants Diana Papove - Director of Corporate Communications Chris Astle - Senior Vice President and Chief Financial Officer Kenneth Galbraith - Chair and Chief Executive Officer Paul Moore - Chief Scientific Officer Conference Call Participants Jon Miller - Evercore Yigal Nochomovitz - Citigroup Charles Zhu - Guggenheim Brian Cheng - JP Morgan Operator Thank you for standing by. This is the conference operator.

Zymeworks Inc. (ZYME) Q2 2023 Earnings Call Transcript

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.97 per share a year ago.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates

VANCOUVER, British Columbia, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the three and six months ended June 30, 2023 and provided a summary of recent business highlights.

Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results

ACM Research

Chimerix

Rocky Brands

Tsakos Energy Navigation Limited

Vital Energy Inc

When dealing with the best small-cap stocks to buy, investors effectively absorb higher risk for the possibility of substantive rewards. Even better, these rewards can come in quickly, enabling those seeking a boost in their portfolio to make up for lost ground.

7 Small-Cap Stocks to Buy Before the Breakout

VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2023 financial results after market close on August 10, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 10, 2023 at 4:30 p.m. Eastern Time (ET).

Zymeworks To Host Second Quarter 2023 Results Conference Call

BioNTech SE

Celularity

Innoviva

Regeneron Pharmaceuticals

Voyager Therapeutics

Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors.

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now

VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Mr. Carlos E. Campoy to its board of directors effective as of June 30, 2023. Mr. Campoy brings extensive strategic and financial leadership experience in the pharmaceutical and biotechnology sectors to the Zymeworks board of directors. He was also appointed as a member of the audit committee and the nominating and corporate governance committee of the board of directors.

Zymeworks Appoints New Director

VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that it is set to join both the Russell 3000®, Russell 2000®, and the Russell Microcap® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.

Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes

Sachem Capital

If you're willing to attempt a difficult balancing act in seeking out a discount and potentially imminent upside momentum at roughly the same time, these adventurous undervalued growth stocks could be up your alley. While it might seem too good to be true, with thousands of tradable securities available, at least a few truly compelling ideas will likely slip under the radar.

The 3 Most Undervalued Growth Stocks for Your June Buy List

Advanced Semiconductor Engineering

Terran Orbital Corp

Growth stocks are often expensive in that they trade with high valuations like price-to-earnings (P/E) and price-to-sales (P/S) ratios. Yet, these high valuations might be justified if the company can continue to grow at a rapid pace.

3 Cheap Growth Stocks That Are Too Good to Pass Up

Jazz Pharmaceuticals

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate (cORR) of 41.3%, median duration of response (DOR) of 12.9 months, and median progression-free survival (PFS) of 5.5 months  (median study follow-up time of 12.4 months) Biliary tract cancers (BTC) are an aggressive group of cancers with no currently approved HER2-targeted treatment option Jazz to host KOL investor webcast June 2, 2023, at 6:45 p.m. CT to review zanidatamab BTC data DUBLIN and VANCOUVER, BC , June 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC).

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

News for Zymeworks Inc Stock (ZYME)